Recombinant Vaccines represent an innovative approach to vaccine development that utilizes genetic engineering techniques to produce vaccines with enhanced safety, efficacy, and specificity. These vaccines are created by inserting genes encoding specific antigens or proteins from a pathogen into a harmless vector, such as a virus or bacterium, which then delivers the antigen to the immune system, stimulating a protective immune response.
One of the key advantages of recombinant vaccines is their ability to produce highly purified antigens that are specific to the target pathogen. By isolating and purifying the antigenic proteins responsible for inducing immunity, recombinant vaccines minimize the risk of unwanted side effects associated with whole-pathogen vaccines. Recombinant vaccines can be designed to target a wide range of pathogens, including viruses, bacteria, and parasites, making them versatile tools for preventing infectious diseases. Examples of recombinant vaccines include those against hepatitis B, human papillomavirus (HPV), and COVID-19. In addition to their specificity, recombinant vaccines offer other advantages over traditional vaccine production methods. They can be produced using well-established manufacturing processes, allowing for rapid scale-up and production of large quantities of vaccine doses. This scalability is particularly important during pandemics or outbreaks when there is an urgent need for vaccines. Furthermore, recombinant vaccines are often safer than traditional vaccines because they do not contain live or inactivated forms of the pathogen. This reduces the risk of vaccine-associated adverse events and allows for their use in immunocompromised individuals or those with underlying health conditions.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States